NCT05270031终止不适用
A Phase 3 Randomized Controlled Clinical Trial: Balloon Dilation Treatment of the Eustachian Tube Using an Endovascular Balloon
适应症
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 15
- 试验地点
- 1
- 主要终点
- Otoscopy, Normal, Retracted or Middle ear effusion
研究概览
简要总结
In this study, patients with dysfunction of the eustachian tube will be included. They will be randomized to one of two treatment groups.
- balloon dilation of the eustachian tube or
- nasal saline Patients will undergo follow-up for one year and will be able to crossover to the treatment arm after three months
详细描述
Patients will eustachian tube dysfunction will be asked to participate in the study.
They will be randomized to one of two groups
group 1 - surgical dilation of the eustachian tube in general anaesthesia
group 2 - daily nasal saline spray, twice a day
Regular Follow up with Tympanogram and Questionnaire
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •≥18 years old (of both sexes)
- •Diagnosed with persistent obstructive eustachian tube dysfunction (OETD) for at least 3 months prior to enrolment uni- and/or bilateral
- •Diagnosis (both required):
- •i. Persistent OETD symptoms assessed by Eustachian Tube Dysfunction Questionnaire (ETDQ-7) with overall score of ≥3 (moderate to severe symptoms) for 3 months or more prior to enrollment.
- •ii. Refractory to medical therapy (minimum of 4 weeks of daily intranasal steroid spray or one completed course of an oral steroid within 3 months before study enrollment).
排除标准
- •Patulous eustachian tube
- •Prior eustachian tube intervention
- •Presence of myringotomy ventilation tube or a tympanic membrane perforation
- •Active chronic or acute otitis media
- •Chronic otitis media with cholesteatoma
- •Fluctuating sensorineural hearing loss or Meniere's disease
- •Chronic rhinosinusitis, allergies, or reflux disease not controlled with medication
- •History of head or neck surgery within 3 months
- •Prior radiation to the head and neck
- •Active temporomandibular joint disorders
- •Cleft palate or Craniofacial syndrome
- •Cystic fibrosis or Ciliary dysmotility syndrome or Systemic immunodeficiencies
- •Active acute upper respiratory infection
- •Nasal endoscopy with evidence of anatomic conditions that would prevent transnasal access to the Eustachian tube
- •CT temporal bone scan with evidence of carotid artery dehiscence, superior semicircular canal dehiscence, or extrinsic eustachian tube compression
- •Patient unable to follow protocol for any reason
结局指标
主要结局
Otoscopy, Normal, Retracted or Middle ear effusion
时间窗: 12 months
Microscopic evaluation of tympanic membrane
次要结局
- Tympanogram(12 months)
- Valsalva maneuver -positive or negative(12 months)
- HUI (Health utility index)(12 months)
- ETDQ-7 (eustachian tube dilation questionnaire - seven)(12 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Study of Safety and Efficacy for the Eustachian Tube Balloon CatheterEustachian Tube DysfunctionNCT02087150Integra LifeSciences Corporation323
已完成
3 期
LUX-Head&Neck 3: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer After Platinum Based ChemotherapyHead and Neck NeoplasmsNCT01856478Boehringer Ingelheim340
进行中（未招募）
不适用
Posterior vs. Anterior Tympanostomy Tube PlacementNCT06191562David Chi, MD386
已完成
不适用
Auricular Neuromodulation for FESSFunctional Endoscopic Sinus SurgeryVagal Nerve StimulationPlatelet ActivationNCT06662422Icahn School of Medicine at Mount Sinai20
已完成
3 期
LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based ChemotherapyHead and Neck NeoplasmsCarcinoma, Squamous CellNCT01345682Boehringer Ingelheim483